Phase IIa Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of KPAX 002 (Methylphenidate Hydrochloride + K-PAX Synergy) as a Treatment for Gulf War Illness in Patients Meeting the Kansas Case Definition
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs KPAX 002 (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- 05 Oct 2017 Last checked against ClinicalTrials.gov record.
- 14 Oct 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 08 Oct 2015 New trial record